Smarcd3 deletion led to a greater significant loss (3-fold) in EpCAM+ tumor cells, and a 3.5-fold reduction in EpCAM+MSI2+ tumor stem cells in secondary transplants (Fig. 2c, d), suggesting that Smarcd3 deletion reduces the self-renewal capability of established tumor cells. The gene discussed is MSI2; the disease is neoplasm.